Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
AEZS

Aeterna Zentaris

$1.63

-0.16 (-8.94%)

16:10
03/05/18
03/05
16:10
03/05/18
16:10
Hot Stocks
Aeterna Zentaris appoints James Clavijo as CFO »

Aeterna Zentaris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEZS

Aeterna Zentaris

$1.79

0.09 (5.29%)

07:47
03/05/18
03/05
07:47
03/05/18
07:47
Hot Stocks
Aeterna Zentaris provides update on class action lawsuit »

Aeterna Zentaris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

, AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

07:33
01/17/18
01/17
07:33
01/17/18
07:33
Conference/Events
Strongbridge Biopharma to host conference call »

Conference call to…

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

07:30
01/17/18
01/17
07:30
01/17/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Aeterna Zentaris »

Aeterna Zentaris trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

, SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

07:14
01/17/18
01/17
07:14
01/17/18
07:14
Hot Stocks
Aeterna Zentaris enters into licensing agreement with Strongbridge Biopharma »

Aeterna Zentaris (AEZS)…

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

SBBP

Strongbridge Biopharma

$8.35

0.35 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEZS

Aeterna Zentaris

$2.07

-0.0999 (-4.60%)

06:55
01/17/18
01/17
06:55
01/17/18
06:55
Hot Stocks
Breaking Hot Stocks news story on Aeterna Zentaris »

Aeterna Zentaris trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEZS

Aeterna Zentaris

$2.45

-0.25 (-9.26%)

16:18
12/22/17
12/22
16:18
12/22/17
16:18
Hot Stocks
Aeterna Zentaris consider counterclaim from Dodd, Theodore 'without merit' »

Aeterna Zentaris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Dec

AEZS

Aeterna Zentaris

$2.01

-0.01 (-0.50%)

08:11
12/21/17
12/21
08:11
12/21/17
08:11
Recommendations
Aeterna Zentaris analyst commentary at Maxim »

Aeterna Zentaris'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Dec

AEZS

Aeterna Zentaris

$2.01

-0.01 (-0.50%)

17:30
12/20/17
12/20
17:30
12/20/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Aeterna Zentaris »

Aeterna Zentaris trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Dec

AEZS

Aeterna Zentaris

$2.01

-0.01 (-0.50%)

17:01
12/20/17
12/20
17:01
12/20/17
17:01
Hot Stocks
Aeterna Zentaris announces FDA approval of Macrilen »

Aeterna Zentaris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.